Hematologic Malignancy
Small Lymphocytic Lymphoma
CI-CAN-00003981SLLExplore in graph →
Hematologic129 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003981SLLExplore in graph →
Clinical trials
479 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (108)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(BOSS) | withdrawn | Phase 2 | 0 | AstraZenecaINDUSTRY | 0 | Jun 5, 2025 | clinicaltrials |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma(BRIO) | withdrawn | Phase 2 | 0 | SecuraBioINDUSTRY |
| 1 |
| Feb 28, 2023 |
| clinicaltrials |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(S-BR) | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 5, 2025source: clinicaltrials